Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A case report of shingles and subsequent cardiac ischaemia in a young male.

European heart journal. Case reports·2026

Same author

Combining plasma biomarkers and cognitive challenge tests enhances prediction of functional trajectories of decline among older adults with cognitive impairment.

Journal of Alzheimer's disease : JAD·2026

Same author

Common Medical Comorbidities, Demographic Factors and Levels of Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration in Black/African American Older Adults.

Biomolecules·2026

Same author

LIBS and Raman spectroscopy for stand-off material and contamination characterisation on a robot for the nuclear industry.

Journal of hazardous materials·2026

Same author

Simultaneous dimension and tolerance design for robot manipulator considering cost and positioning accuracy reliability.

The International journal, advanced manufacturing technology·2026

Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026

Search research articles

Related Experiment Videos

The NINDS Parkinson's disease biomarkers program.

Liana S Rosenthal¹, Daniel Drake², Roy N Alcalay³

¹Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Movement Disorders : Official Journal of the Movement Disorder Society

|October 8, 2015

Summary

The Parkinson's Disease Biomarkers Program accelerates discovery of new biomarkers for Parkinson's disease (PD) diagnosis and progression. This initiative provides crucial data and biosamples to researchers, aiding in the development of future PD therapies.

Keywords:

Parkinsonism biofluids data management disease-modifying strategies

Related Experiment Videos

Area of Science:

Neuroscience
Biomarker Research
Clinical Trials

Background:

Neuroprotection for Parkinson's disease (PD) is a significant challenge in neurological research.
Biomarkers are essential for overcoming obstacles in developing effective PD therapies.
The National Institute of Neurological Disorders and Stroke established the Parkinson's Disease Biomarkers Program to discover PD biomarkers for clinical trials.

Purpose of the Study:

To develop clinical and laboratory-based biomarkers for PD diagnosis, progression, and prognosis.
To facilitate biomarker discovery through a novel consortium design.
To create a shared resource for the research community to advance PD biomarker projects.

Main Methods:

Utilized a consortium design with standardized operating procedures and pooled reference samples.
Established a web-based Data Management Resource for rapid sharing of data and biosamples.
Recruited participants and collected biosamples across multiple consortium projects.

Main Results:

As of October 2014, 1,082 participants (620 PD, 101 parkinsonism, 23 essential tremor, 338 controls) enrolled.
Over 6,800 biosamples collected, including DNA, RNA, whole blood, plasma, serum, and cerebrospinal fluid (CSF).
Quality control confirmed high quality for nearly all plasma, serum, and CSF samples.

Conclusions:

The program accelerates PD biomarker research by providing widely available samples and data.
Stringent operating procedures and hypothesis testing enhance biomarker discovery.
This resource complements existing programs, fostering collaborative advancements in Parkinson's disease research.